NPCE NeuroPace Inc
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1528287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY21.1%
TTM EPS YoY25.3%
Revenue 3-yr CAGR16.3%
Net income 3-yr CAGR—
Margins
Gross margin81.4%
Operating margin-15.4%
Net margin-20.0%
FCF margin-13.1%
EBITDA margin-15.0%
Returns
ROE-126.1%
ROA-18.7%
ROIC (approx.)-19.7%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets87.9%
Debt / equity5.15x
Current ratio5.26x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $23.10M | $22.83M | $22.07M | $26.59M | $23.35M | $19.50M | $22.52M | $21.47M |
| Cost of revenue | $3.63M | $3.92M | $4.02M | $6.01M | $4.18M | $3.29M | $5.18M | $5.28M |
| Gross profit | $19.47M | $18.91M | $18.05M | $20.58M | $19.17M | $16.21M | $17.34M | $16.19M |
| R&D expense | $6.17M | $6.90M | $7.19M | $7.03M | $6.58M | $6.84M | $7.44M | $6.05M |
| SG&A expense | $4.22M | $5.03M | $4.84M | $4.38M | $4.59M | $6.07M | $4.05M | $3.84M |
| Operating income | -$2.08M | -$5.14M | -$5.57M | -$1.77M | -$4.03M | -$8.19M | -$5.15M | -$3.65M |
| Interest expense | $1.56M | $1.54M | $1.52M | $1.60M | $1.65M | $2.06M | $2.15M | $2.19M |
| Income tax | — | — | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$3.30M | -$6.20M | -$6.69M | -$2.73M | -$3.50M | -$8.65M | -$6.59M | -$5.25M |
| EBITDA | -$1.98M | -$5.04M | -$5.51M | -$1.69M | -$3.92M | -$8.09M | -$5.10M | -$3.60M |
| EPS (basic) | -0.10 | -0.18 | -0.20 | — | -0.11 | -0.26 | -0.21 | — |
| EPS (diluted) | -0.10 | -0.18 | -0.20 | — | -0.11 | -0.26 | -0.21 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 34.35M | 34.10M | 33.72M | — | 33.13M | 32.86M | 31.48M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.23M | $12.54M | $14.78M | $21.69M | $20.65M | $22.86M | $27.02M | $13.55M |
| Short-term investments | $39.00M | $39.16M | $39.20M | $39.37M | $39.37M | $39.28M | $39.24M | $39.33M |
| Receivables | $14.28M | $14.93M | $14.79M | $12.94M | $14.94M | $13.55M | $15.44M | $12.85M |
| Inventory | $18.80M | $18.11M | $16.69M | $14.86M | $18.14M | $16.35M | $13.58M | $13.38M |
| Current assets | $84.54M | $86.19M | $86.98M | $94.07M | $95.33M | $93.74M | $97.48M | $81.34M |
| PP&E, net | $1.16M | $1.24M | $1.28M | $1.12M | $1.11M | $1.16M | $1.16M | $1.05M |
| Total assets | $94.78M | $96.99M | $98.90M | $105.56M | $107.25M | $106.11M | $110.20M | $94.65M |
| Current liabilities | $16.07M | $17.43M | $16.17M | $17.81M | $19.61M | $17.14M | $14.71M | $15.16M |
| Long-term debt | $59.16M | $59.01M | $59.02M | $58.88M | $58.75M | $58.62M | $59.79M | $59.52M |
| Total debt | $59.16M | $59.01M | $59.02M | $58.88M | $58.75M | $58.62M | $59.79M | $59.52M |
| Total liabilities | $83.28M | $85.11M | $84.44M | $86.53M | $88.74M | $86.68M | $85.94M | $86.63M |
| Shareholders' equity | $11.49M | $11.88M | $14.45M | $19.03M | $18.52M | $19.44M | $24.27M | $8.01M |
| Net debt | $48.92M | $46.48M | $44.24M | $37.19M | $38.10M | $35.76M | $32.77M | $45.97M |
| Shares outstanding | 34.43M | 34.28M | 33.91M | 33.57M | 33.28M | 33.04M | 32.75M | 30.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.76M | -$3.90M | -$5.90M | $506,000 | -$1.94M | -$2.09M | -$7.48M | -$4.80M |
| Capital expenditure | $16,000 | $125,000 | $117,000 | $97,000 | $30,000 | $168,000 | $37,000 | $39,000 |
| Free cash flow | -$2.78M | -$4.03M | -$6.02M | $409,000 | -$1.97M | -$2.25M | -$7.52M | -$4.84M |
| Investing cash flow | -$16,000 | -$125,000 | -$117,000 | -$97,000 | -$30,000 | -$168,000 | -$37,000 | $1.96M |
| Financing cash flow | $477,000 | $1.18M | -$166,000 | $635,000 | -$235,000 | -$1.91M | $21.11M | $848,000 |
| Depreciation & amortization | $100,000 | $100,000 | $60,000 | $80,000 | $100,000 | $100,000 | $49,000 | $48,000 |
| Stock-based compensation | $2.43M | $2.30M | $2.28M | $2.61M | $2.63M | $3.23M | $2.63M | $2.60M |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | $0 | $49.55M | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.